通过对表达特征的分析来识别与心力衰竭相关的关键基因
Che Wang1, Qingmin Li1, Honghui Yang1
1Department of Cardiology, Henan Provincial People's Hospital, Fuwai Central China Cardiovascular Hospital, People's Hospital of Zhengzhou University, Zhengzhou, Henan, China.
Archives of medical science : AMS
|May 17, 2024
概括
这项研究确定了与心力衰竭 (HF) 病原发生相关的关键基因和微RNA. 观察到GAPDH,GALM1,MMP9,CCL5和GNAL2的水平增加,特定的microRNA被确定为HF治疗的潜在药物标.
科学领域:
- 生物医学科学 生物医学科学
- 基因组学就是基因组学.
- 分子生物学分子生物学
背景情况:
- 心力衰竭 (HF) 是一种复杂的临床综合征,具有显著的发病率和死亡率.
- 识别新型生物标志物对于理解HF病原和开发有效治疗方法至关重要.
研究的目的:
- 为了阐明心力衰竭 (HF) 发病过程中的候选生物标志物.
- 使用基因表达总 (GEO) 数据集在HF中分析差异表达基因 (DEG).
- 确定关键分子和HF的潜在治疗点.
主要方法:
- 从高频率和对照对象中分析GSE76701基因表达特征.
- 使用ClueGO + CluePedia和基因和基因组的京都百科全书 (KEGG) 识别DEG和丰富分析.
- 构建蛋白质-蛋白质相互作用 (PPI) 和药物-mRNA-miRNA网络以识别枢纽基因和治疗点.
主要成果:
- 在HF和对照组之间,共发现了489种DEG,富含I型干扰素和白细胞迁移通路.
- 鉴定出GAPDH,GALM1,MMP9,CCL5和GNAL2是枢纽基因,它们的HF水平显著增加.
- 在HF背景下,FCGR2B,CCND1和NF-κb以及miRNA-605-5p,miRNA-147a和miRNA-671-5p被确定为药物标.
结论:
- 核心基因GAPDH,GALM1,MMP9,CCL5和GNAL2在心力衰竭中显著上调.
- 预计miRNA-605-5p,miRNA-147a和miRNA-671-5p将成为关键的microRNAs,在HF病变发生过程中与药物标相互作用.
- 这些发现突出了新型心力衰竭治疗的潜在分子标.
相关概念视频
01:17Pathophysiology of Heart Failure
1.6K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.6K
01:11Genome-wide Association Studies-GWAS
13.3K
Genome-wide association studies or GWAS are used to identify whether common SNPs are associated with certain diseases. Suppose specific SNPs are more frequently observed in individuals with a particular disease than those without the disease. In that case, those SNPs are said to be associated with the disease. Chi-square analysis is performed to check the probability of the allele likely to be associated with the disease.
GWAS does not require the identification of the target gene involved in...
GWAS does not require the identification of the target gene involved in...
13.3K
01:22Heart Failure Drugs: β-Blockers
337
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
337
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
422
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
422
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
80
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
80